Oral Treprostinil in PAH: The FREEDOM-EV Study

In this animated video article, we present the FREEDOM-EV study, the evaluation of the safety and efficacy of oral treprostinil, in combination with another treatment, in people with pulmonary arterial hypertension (PAH).

PAH is a rare, progressive disease, where symptoms of shortness of breath, chest pain, tiredness, and dizziness get worse over time. When arteries in the lungs are squeezed too tightly and narrow, blood pressure in the lungs become abnormally high. The heart has to work harder and harder to circulate blood throughout the body, causing the heart to weaken and may lead to heart failure or death. Unfortunately, there is no known cure for PAH, but medication may help reduce symptoms.

Oral treprostinil (Orenitram®) can help patients with PAH and improve their ability to stay active. This medication works by relaxing the blood vessels and slows down the thickening of arteries in the lungs. The FREEDOM-EV study aimed to investigate oral treprostinil with a person’s current PAH treatment and its effects on clinical worsening.

Click here to watch our animated video presenting a a sub-study of the FREEDOM-EV study.

Original Article

White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. 2020;201(6):707-717. doi:10.1164/rccm.201908-1640OC